Bernd Jilma Selected Research

Inflammation

02/2008	In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model.
03/2007	The tumor necrosis factor alpha -308 G/A polymorphism does not influence inflammation and coagulation response in human endotoxemia.
10/2006	The C-reactive protein (+)1444C/T alteration modulates the inflammation and coagulation response in human endotoxemia.
12/2005	The effects of supra-normal protein C levels on markers of coagulation, fibrinolysis and inflammation in a human model of endotoxemia.
03/2005	Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation.
09/2004	Angiotensin receptor blockade decreases markers of vascular inflammation.
12/2003	Regulation of Fas (APO-1, CD95) and Fas ligand expression in leukocytes during systemic inflammation in humans.
11/2003	Regulation of protease-activated receptor 1 (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans.
10/2003	Effects of enalapril on disseminated intravascular thrombin formation during systemic inflammation.
09/2003	Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia.
11/2002	Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation.
10/2002	Point of care measurement of lepirudin and heparin anticoagulation during systemic inflammation.
05/2002	Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans.

Articles by Research Topic

Disease

17	Endotoxemia 04/2008 - 01/2003
13	Inflammation 02/2008 - 05/2002
3	Stroke (Strokes) 01/2006 - 04/2003
1	Cardiovascular Diseases (Cardiovascular Disease) 03/2008
1	Acute Coronary Syndrome 03/2008
1	Chronic Hepatitis C 10/2006
1	Thrombocytopenia (Thrombopenia) 10/2006
1	Melanoma (Melanoma, Malignant) 10/2006
1	Venous Thromboembolism 08/2006
1	Anemia 07/2006
1	Movement Disorders (Movement Disorder) 06/2003
1	Poisoning 05/2003
1	Tissue Adhesions 05/2003

Drug/Important Bio-Agent (IBA)

5	Thromboplastin (Tissue Factor)IBA 06/2004 - 05/2002
3	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2006 - 04/2003
3	ThrombinIBA 01/2006 - 10/2003
3	Interleukin-6 (Interleukin 6)IBA 01/2006 - 01/2004
2	von Willebrand FactorIBA 03/2008 - 03/2005
2	ErythropoietinIBA 10/2006 - 07/2006
2	E-SelectinIBA 08/2006 - 03/2005
2	Protein CIBA 12/2005 - 09/2003
2	Enalapril FDA LinkGeneric 10/2003 - 05/2003
1	1,6- bis(3- (3- carboxymethylphenyl)- 4- (2- alpha- D- mannopyranosyloxy)phenyl)hexaneIBA 04/2008
1	Simvastatin (Zocor)FDA LinkGeneric 02/2008
1	rosuvastatin (Crestor)FDA Link 02/2008
1	AntigensIBA 01/2008
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2007
1	Fibrinogen (Factor I)IBA 01/2007
1	C-Reactive ProteinIBA 10/2006
1	Epidermal Growth Factor (EGF)IBA 10/2006
1	Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric 07/2006
1	Dipyridamole (Persantine)FDA LinkGeneric 01/2006
1	Annexin A5IBA 01/2006
1	Toll-Like Receptor 4IBA 11/2005
1	Carbon MonoxideIBA 02/2005
1	Aggrenox FDA Link 09/2004
1	AngiotensinsIBA 09/2004
1	eptifibatide (Integrilin)FDA Link 12/2003
1	tirofiban (Aggrastat)FDA Link 12/2003
1	Fas Ligand Protein (Fas Ligand)IBA 12/2003
1	PAR-1 ReceptorIBA 11/2003
1	thrombin receptor peptide SFLLRNPIBA 11/2003
1	drotrecogin alfa activated (Xigris)FDA Link 09/2003
1	TiaprideIBA 06/2003
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 05/2003
1	clopidogrel (Plavix)FDA LinkGeneric 04/2003
1	Factor X (Stuart Factor)IBA 11/2002
1	Heparin (Liquaemin)FDA LinkGeneric 10/2002
1	lepirudin (Refludan)FDA Link 10/2002
1	AcenocoumarolIBA 05/2002